期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 12, 期 6, 页码 673-684出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2012.675323
关键词
adoptive cell therapy; CIK cells; immunotherapy; solid tumors
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [2011/2014]
- Associazione Italiana contro le Leucemie-linfomi e mieloma (AIL)
- Associazione Donatrici Italiane Sangue Cordone Ombelicale (ADISCO, ONLUS)
- Assegno di Ricerca
- Regione Piemonte
- Associazione Piemontese contro le Leucemie (APL)
- Associazione Donatrici Italiane Sangue Cordone Ombelicale
Introduction: Cytokine-induced killer (CIK) cells are heterogeneous ex vivo-expanded T lymphocytes with mixed T-NK phenotype and endowed with a wide MHC-unrestricted antitumor activity. CIK cells can be expanded from peripheral blood mononuclear cells (PBMC) cultured with the timed addition of IFN-gamma, Ab anti-CD3 and IL2. A consistent subset of mature CIK cells presents a CD3(+)CD56(+) phenotype. The CD3(+)CD56(+) cellular subset is the main responsible for the tumor-killing activity, mostly mediated by the interaction of NKG2D receptor with MHC-unrestricted ligands (MIC A/B; ULBPs) on tumor cells. Areas covered: In the present work, we described the biologic characteristics of CIK cells, focusing on those aspects that may favor their clinical translation. We reviewed preclinical data and analyzed reports from clinical trials. A specific paragraph is dedicated to future research perspectives in the field. Expert opinion: CIK cells represent a realistic new option in the field of cancer immunotherapy. Crucial issues, favoring their clinical translation, are the easy availability of large amounts of expanded CIK cells and their MHC-unrestricted tumor killing, potentially effective against many tumor types. Intriguing future perspectives and open challenges are the investigation of synergisms with other immunotherapy approaches, targeted therapies or even conventional chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据